InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$432.49

2026-10-16

Market Cap

$233.8B

Volume

2.6M

52-Wk High

$447.03

52-Wk Low

$288.00

Trailing PE

26.7

P/S

6.13

Gross Margin

72.7%

Net Margin

22.9%

ROE

89%

ROIC

14%

Piotroski

8/9

Altman Z

2.3

1-Yr Return

+50.3%

5-Yr Return

+163.0%

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNASDAQMarket Cap$233.8BEmployees31,500 (SEC-filed)CEORobert A. BradwayIPO1983-06-17CountryUS

One Amgen Center Drive, Thousand Oaks, CA 91320-1799 · Tel 805 447 1000 · amgen.com

INSIDERSTREET SCORE67 / 100Street mean $404.64 (25 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$12M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · AMGN +50.3% · S&P 500 +15.9% · spread +34.4pp

7 Years vs S&P 500 · AMGN +163.0% · S&P 500 +189.9% · spread -26.8pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE67of 100

Score Breakdown

Profitability	88/100
Growth	74/100
Momentum	91/100
Quality	69/100
Earnings Quality	67/100
Balance Sheet	41/100
Value	43/100
Risk (safety)	50/100
Overall	67.3/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
AZN	71
GILD	44
NVS	65
PFE	46
MRK	49
BMY	68
AMGN	67

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 67 in 26 Q2, latest 67 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY67 / 100IS Score 67.3 / 100 · +0.0 from peak of 67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 92 / 100 · Power +83 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 67 and price structure at 92 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 67.3	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 61 → 63 → 65 → 67	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 3,172 → now 3,172	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)6 buys2026-09-22

Insider Buys (180d)0none disclosed

ETF Funds (30d)1787 up / 1434 downnet +353 funds

Institutions Added (13F)19managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 3,172 · latest 3,172 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	3,172	462.0M	$164.3B	85.6%
2026 Q1	3,153	435.2M	$151.5B	80.6%
2025 Q4	3,103	444.0M	$143.5B	82.2%
2025 Q3	2,827	423.1M	$118.1B	78.3%
2025 Q2	2,866	432.8M	$119.6B	80.2%
2025 Q1	2,939	429.0M	$132.1B	79.4%
2024 Q4	2,868	418.5M	$107.5B	77.5%
2024 Q3	2,831	410.1M	$129.5B	75.9%
2024 Q2	2,796	413.4M	$127.2B	76.5%
2024 Q1	2,726	409.9M	$114.7B	75.9%
2023 Q4	2,725	410.9M	$116.2B	76.1%
2023 Q3	2,512	406.4M	$107.5B	75.2%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Dittrich Thomas J.W.	EVP & CFO	2026-09-04	—	17,201	$7.07M	0
Khosla Rachna	SVP, Business Development	2026-08-13	EXERCISE	1,252	$0.20M	7,656
Khosla Rachna	SVP, Business Development	2026-08-13	SELL	1,252	$0.52M	6,404
Khosla Rachna	SVP, Business Development	2026-08-13	EXERCISE	1,252	$0.20M	0
Khosla Rachna	SVP, Business Development	2026-08-11	SELL	2,000	$0.83M	6,404
Busch Matthew C.	VP, Finance & CAO	2026-08-07	A-Award	730	—	5,080
Ishrak Omar	director	2026-08-07	A-Award	85	—	7,486
Holley Charles M	director	2026-08-07	A-Award	103	—	12,990

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	6	31,601	$12.1M	Counted
M — Exercises (paired A/D)	8	182,686	$29.4M	None — mechanics
F — Tax withholding	53	161,838	$59.5M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$12.1M6 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-13	Khosla Rachna	1,252	$0.5M
2026-08-11	Khosla Rachna	2,000	$0.8M
2026-08-06	Grygiel Nancy A.	2,970	$1.2M
2026-08-06	Derek Miller	3,890	$1.6M
Trailing 12 mo	11 filings	80,719	$31M

Filed	Form	Reporting person	% of class	Shares
2026-05-14	SCHEDULE 13G	Capital World Investors	5.50%	29.6M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-09-08	SCHEDULE 13G/A	The Vanguard Group	10.00%	53.9M sh
2025-04-17	SCHEDULE 13G/A	BlackRock, Inc.	7.60%	40.8M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
David Taylor	House	BUY	$1,001 - $15,000	2026-09-22	2026-10-02
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
David Taylor	House	SELL	$1,001 - $15,000	2026-08-26	2026-09-07
Sheldon Whitehouse	Senate	SELL	$1,001 - $15,000	2026-08-12	2026-09-02
Sheldon Whitehouse	Senate	SELL	$1,001 - $15,000	2026-08-12	2026-09-02
Sheldon Whitehouse	Senate	SELL	$1,001 - $15,000	2026-08-12	2026-09-01

House 12-Mo33 trades16 purchases

Senate 12-Mo13 trades0 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)3,153

13F Shares435M80.6% of shares out

New / Closed226 / 126positions, QoQ

Increased / Reduced1,216 / 1,251positions, QoQ

Put/Call (13F)0.89option positions

Free Float99.7%539M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	1.1M	$455M
Smead Capital Management, Inc.	586,504	$247M
Forum Financial Management, Lp	347,857	$147M
Wealth Enhancement Advisory Servic	340,323	$109M
Ferguson Wellman Capital Managemen	243,747	$103M
Sarasin & Partners Llp	180,232	$76M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.3%	$7.2B
VTSAX	0.3%	$7.2B
VSMPX	0.3%	$7.2B
VTI	0.3%	$7.2B
VFINX	0.3%	$6.0B
VFFSX	0.3%	$6.0B

13F Filers Holding AMGN — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session43.8%2026-10-15

20-Day Avg54.2%50-day 52.2%

TrendRising20d vs 50d

By Market CenterQ: 43% · N: 64% · B: 41%latest session

Weekly Notional ($B)

Where AMGN Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	2.9M	32 sh
Ubsa Ubs Ats	2.6M	37 sh
Sgmt Sigma X2	1.5M	27 sh
Ebxl Level Ats	1.5M	20 sh
Mlix Instinct X	1.4M	42 sh
Bids Bids Ats	1.3M	345 sh

Where a dollar of Amgen Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$26.4B	72%
Non-US	$10.3B	28%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

AMGN (live moat model)Peer median: AZN · GILD · NVS · PFE · MRK

Component scores from the live moat model. Peer median illustrative.

Moat score 58/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert A. Bradway	Chairman & CEO
James E. Bradner	EVP of Research & Development, Artificial Intelligence and Data
Peter H. Griffith	Executive Vice President
Thomas J. W. Dittrich	Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+12.1%

Next Report2026-11-03

Income Quality1.43OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+2.2%	+1.3%	+7.1%	+18.6%	+9.9%
Gross profit	+1.3%	+2.0%	-0.7%	+4.0%	+26.5%
Operating income	-16.4%	+25.2%	-17.4%	-8.1%	+47.1%
Net income	-18.9%	+11.2%	+2.5%	-39.1%	+88.5%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	26.0	26.3	28.2	33.4	36.7
Cost of revenue	6.5	6.4	8.4	12.9	10.7
Gross profit	19.5	19.9	19.8	20.6	26.0
R&D expense	6.3	4.4	4.8	6.0	7.0
SG&A expense	5.4	5.4	6.2	7.1	7.1
Operating income	7.6	9.6	7.9	7.3	10.7
EBITDA	11.3	12.2	14.8	13.4	15.8
D&A	3.4	3.4	4.1	5.6	5.2
Pretax income	6.7	7.3	7.9	4.6	9.0
Income tax	0.8	0.8	1.1	0.5	1.3
Net income	5.9	6.6	6.7	4.1	7.7
Diluted EPS ($)	10.28	12.11	12.49	7.56	14.23
Diluted shares (M)	573	541	538	541	542

Operating CF$10B

CapEx$2B

Free cash flow$8B

SBC$0B

Buybacks$0B

Net cash change$-3B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	7.6	10.9	12.0	9.1
ST investments	1.7	0.0	0.0	0.0
Receivables (net)	6.4	7.9	7.5	9.6
Total current assets	22.2	30.3	29.0	29.1
PP&E (net)	5.4	5.9	6.5	7.9
Goodwill + intangibles	31.6	51.3	46.3	41.0
Total assets	65.1	97.2	91.8	90.6
Accounts payable	1.6	1.6	1.9	20.9
Short-term debt	1.6	1.4	3.6	4.6
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	15.7	18.4	23.1	25.5
Long-term debt	37.4	63.2	56.5	50.0
Total liabilities	61.5	90.9	86.0	81.9
Shareholders' equity	3.7	6.2	5.9	8.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.6	6.7	4.1	7.7
D&A	3.4	4.1	5.6	5.2
Stock-based compensation	0.4	0.4	0.5	0.0
Working capital change	(0.7)	(0.5)	2.4	(2.0)
Operating cash flow	9.7	8.5	11.5	10.0
Capital expenditures	(0.9)	(1.1)	(1.1)	(1.9)
Investing cash flow	(6.0)	(26.2)	(1.0)	(1.9)
Buybacks	(6.4)	0.0	(0.2)	0.0
Dividends paid	(4.2)	(4.6)	(4.8)	(5.1)
Debt issuance / (repay)	6.6	25.7	(4.3)	(5.7)
Financing cash flow	(4.0)	21.0	(9.4)	(10.9)
Free cash flow	8.8	7.4	10.4	8.1

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	73.2%	126.5%	135.8%	67.6%	106.1%	89%
ROA	9.5%	10.4%	8.3%	4.3%	8.5%	9.1%
ROIC	21.0%	25.6%	11.3%	11.9%	16.3%	14.2%
Gross margin	75.2%	75.7%	70.1%	61.5%	70.8%	72.7%
Operating margin	29.4%	36.3%	28.0%	21.7%	29.1%	33.2%
Net margin	22.7%	24.9%	23.8%	12.2%	21.0%	22.9%
EBITDA margin	43.5%	46.2%	52.5%	40.0%	43.1%	46.2%
FCF margin	32.3%	33.4%	26.1%	31.1%	22.0%	—
VALUATION
P/E	19.00	19.63	21.77	33.45	23.05	26.7
P/B	16.71	35.13	23.46	23.28	20.53	20.0
P/S	4.31	4.89	5.19	4.09	4.83	6.13
P/FCF	13.36	14.64	19.87	13.16	21.94	23.0
EV/EBITDA	12.15	13.01	13.50	13.85	13.20	15.7
EV/Revenue	5.28	6.01	7.09	5.53	6.07	7.3
Earnings yield	5.3%	5.1%	4.6%	3.0%	4.3%	3.74%
FCF yield	7.5%	6.8%	5.0%	7.6%	4.6%	4.35%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.59	1.41	1.65	1.26	1.14	1.37
Quick ratio	1.26	1.10	1.13	0.95	0.90	1.13
Debt / equity	4.97	10.64	10.37	10.23	6.31	4.90
Debt / assets	54.5%	59.8%	66.5%	65.4%	60.3%	59.9%
Net debt / EBITDA	2.24	2.44	3.63	3.60	2.69	2.46
Interest coverage	6.60	6.22	3.73	2.46	4.24	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.42	0.42	0.35	0.35	0.40	0.40
Receivables turnover	5.52	5.03	4.39	4.76	4.50	3.7
DSO (days)	66	73	83	77	81	98
DPO (days)	79	84	68	50	383	702
Cash conversion cycle	213	246	327	261	-80	-386
GROWTH (YoY)
Revenue growth	2.2%	1.3%	7.1%	18.6%	10.0%	—
Net income growth	-18.9%	11.2%	2.5%	-39.1%	88.5%	—
EPS growth	-16.0%	16.5%	2.3%	-39.3%	88.2%	—
FCF growth	-15.2%	4.8%	-16.2%	41.2%	-22.1%	—
PER SHARE ($)
EPS (diluted, TTM)	10.43	12.16	12.44	7.55	14.20	16.19
Book value / share	11.86	6.79	11.54	10.84	15.94	21.64
Revenue / share	45.98	48.84	52.20	61.67	67.71	70.60
FCF / share	14.83	16.30	13.63	19.18	14.92	18.84
Cash / share	14.22	17.26	20.27	22.09	16.81	25.91
SHAREHOLDER RETURN & SCORES
Buyback yield	4.4%	4.9%	0.0%	0.1%	0.0%	—
Altman Z-Score	1.66	1.61	1.38	1.25	2.18	2.3
Piotroski F-Score	5	5	4	6	7	8/9
Beneish M-Score	-2.43	-2.63	-2.14	-2.91	-2.47	-2.56

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	2.3	Grey zone	Grey
Income quality	1.43	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.56	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.85
Interest burden	0.79
Operating margin	34.0%
Asset turnover	0.42×
Financial leverage	9.60×
= ROE	91%

Growth Quality (live)	Value
Revenue stability	0.90
Earnings stability	0.08
Earnings persistence	0.87
Revenue CAGR 3y	12.8%
EPS CAGR 3y	2.7%
FCF CAGR 3y	1.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.00%

Dividend Yield2.30%

Total Shareholder Return2.68%cash yield

SBC / Revenue1.3%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
BMY	$122.1B	13.2	47%	25.6%	+3.1%	8/9	—
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

41 Analysts

Str Sell (0)Sell (3)Hold (16)Buy (22)Str Buy (0)

Mean Target (qtr)$404.6425 targets

Target vs. Price-6.4%last-quarter mean

Next Report2026-11-03street $5.77

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$39.00B	$39.55B / $38.54B	$23.04	$23.32 / $22.59	20
FY2027	$40.45B	$41.94B / $39.15B	$24.51	$26.03 / $22.82	19
FY2028	$41.78B	$47.20B / $38.09B	$25.90	$29.24 / $21.03	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$422.88	-2.2%	8
Last Quarter	$404.64	-6.4%	25
Last Year	$374.44	-13.4%	59
All Time	$330.04	-23.7%	116

Rolling mean of published targets vs. last close $432.49. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

5/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

2/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

AMGN +50.3% vs S&P 500 +15.9% — spread +34.4pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$413.39	+19.10	+4.62%	Above
SMA 50	$414.52	+17.97	+4.34%	Above
SMA 200	$365.67	+66.82	+18.27%	Above
EMA 9	$421.08	+11.41	+2.71%	Above
EMA 21	$414.51	+17.98	+4.34%	Above
EMA 50	$406.49	+26.00	+6.40%	Above
EMA 200	$368.77	+63.72	+17.28%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +8322 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%94

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago18%+82 pts since

12 Weeks Ago100%+0 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$413.39

Price vs SMA 50$414.52

Price vs SMA 200$365.67

EMA 9/21 Cross421.1/414.5

SMA 50/200Golden

ADX DirectionADX 24

Supertrend$404

Parabolic SAR$398

SMA Slope2.340

RSI62.5

Stochastic K/D86/79

StochRSI K/D96/81

Williams %R-20

CCI175

TSI vs Signal12.5

CMO25.1

ROC7.31%

OBV SignalAccum

Chaikin MF0.090

MFI54

Force Index9M

Elder Ray Bull24.31

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 79

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$436.40 / $439.39 / $444.74	S1 / S2	$431.05 / $428.06
Bollinger (20,2)	$392.90 – $433.88	Squeeze	Off
52-wk range	$280.23 – $447.03	Off 52-wk high	-3.2%
ATR (14)	$10.66 (2.5%)	Historical vol	29.1%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+0.6%Jan55%

-1.2%Feb35%

+0.0%Mar57%

+0.5%Apr45%

-0.0%May50%

+1.6%Jun60%

+5.8%Jul80%

+0.4%Aug55%

+0.2%Sep50%

+1.1%Oct55%

+1.1%Nov60%

-0.2%Dec45%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	AMGN	S&P 500
Weekly volatility (σ, 1y)	3.90%	1.83%
Best / worst week (1y)	+8.1% / -13.6%	—
Max drawdown (5y, monthly)	-21.6%	—
1-week VaR (95%)	-4.6%	—
Beta (5y)	0.43	1.00

AMGN EQUITY WEATHER (LIVE)PARTLY CLOUDY · +22

Trend+41

Momentum+53

Volume+42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 513 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+22.1+31.6 vs industry

Trend+41.2+45.3 vs industry

Momentum+53.3+43.4 vs industry

Volume+42.4+25.8 vs industry

Reading	AMGN	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+22.1	-9.5	-24.0	-20.5
Trend	+41.2	-4.1	-25.6	-21.3
Momentum	+53.3	+9.9	-28.5	-15.8
Volume	+42.4	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert A. Bradway Chief Executive Officer an	$24.7M	67% equity+incentive
James E. Bradner Executive Vice President, R	$8.6M	58% equity+incentive
Peter H. Griffith Executive Vice President a	$8.6M	62% equity+incentive
Murdo Gordon Executive Vice President, Globa	$8.5M	63% equity+incentive
David M. Reese Executive Vice President and	$8.3M	62% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	65
Social	52
Governance	67
Composite ESG	61

Composite ESG Trend

Filed	8-K contents	Items
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-07-31	Other Events	8.01
2026-05-20	Shareholder Vote	5.07
2026-05-19	Officer/Director Change	5.02
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-04-22	Officer/Director Change; Exhibits	5.02,9.01
2026-02-19	Entry into Material Definitive Agreement; Financial Statements and Exh	1.01,9.01
2026-02-03	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-28 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	118 rows · 1997 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-06 to 2026-09-04
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-04-17 to 2026-05-14
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Amgen Inc. (AMGN)

Institutions holding — 12 quarters

Amgen Inc. (AMGN)

Monthly Net Insider Flow (000 shares)

Signal Summary

Amgen Inc. (AMGN)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding AMGN — quarterly

Institutional Put/Call — quarterly

Amgen Inc. (AMGN)

Where AMGN Trades in the Dark

Amgen Inc. (AMGN)

3.8 · Employees (SEC filings)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Balance Sheet — Full

Cash Flow Statement — Full

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Street Price Target — Trajectory

Third-Party Composite Rating

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Family Scores (site weights)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)

Amgen Inc. (AMGN)